Blog
Panelists observe FDA sea changes in inspections, manufacturing, and drug & device reviews
As part of the Hogan Lovells Horizons 2025 life sciences event series, our cross-practice team recently gathered in Boston to discuss shifting regulatory paradigms under the Trump administration’s Food and Drug Administration (FDA)….
By: Hogan Lovells